Published in The Lancet · View the paper (DOI)
A landmark study confirms that chemotherapy with tamoxifen improves survival rates for postmenopausal women with estrogen receptor-positive breast cancer. A second study identifies a subset of patients who may not benefit from chemotherapy despite being at higher risk, suggesting a potential need to reassess treatment guidelines.
Coverage from 2 institutions